Overview of
The Beverlee Zell-Tamis, Ph.D.
Primary Peritoneal Carcinoma Program
Because of our Generous Supporters, ICAN PPC patients involved in
The Beverlee Zell-Tamis, Ph.D. Primary Peritoneal Carcinoma Program
have access to the following information services:
- A review and analysis of the patient's pathology report relating to TNM staging ("Tumor Node Metastasis"); review of the patient's medical history, diet, lifestyle and risk factors, current condition as well as any comorbid factors; and complete review of symptoms prior to presentation.
- Referrals, at the patient's request, to medical oncologists, radiation oncologists, surgical oncologists, radiologists, interventional radiologists, anesthesiologists, and additional specialists relevant to the patient's ongoing care.
- Referrals to support groups that may be of assistance in handling the emotional impact that cancer has on the patient and the patient's family.
- Referrals to PPC-specific organizations that may be of assistance in addressing insurance issues or employment termination issues (because of diagnosis or disclosure of metastatic disease).
- Review of the nature/amelioration of specific side effects from chemotherapy (such as nausea and neuropathy) as well as from other treatment modalities.
- Discussion of the interaction of diet with cancer chemotherapy drugs based on recent studies.
- Delineation of the symptoms about which the PPC patient should alert his/her oncologist.
- Discussion of relevant PPC imaging technology.
- Discussion of pain management issues and treatment options that can be addressed with the patient's medical team.
- Explanation of the recommendations given or not given by the patient's oncology team; assistance in answering the patient's questions which remain either after or between appointments with the medical team.
- Review of the relevant radiotherapy/interventional radiology options which the patient, in turn, may discuss with his/her medical team.
- Discussion of the relevance of the patient's specific immunohistochemistry and cytogenetic results to available clinical trials so that the patient may explore all options with her medical team.
- Analysis of relevant PPC clinical trials options as well as the nature and purpose of clinical trials using Remission Coach®.
- Review of relevant PPC-specific drugs in the anticancer pipeline. Review of all relevant and complementary and alternative medicine ("CAM") avenues.
- Review of the merits of filing a "Single Patient IND for Compassionate or Emergency Use" for a specific experimental cancer drug, if relevant to the patient's situation.
- Exploration of options that might reduce travel costs for the patient as well as ICAN supporters who have volunteered to host a clinical trials patient in a particular city.
The Beverlee Zell-Tamis, Ph.D. Primary Peritoneal Carcinoma Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.
To support this program, please click below.
ICAN is currently working on the The Beverlee Zell-Tamis, Ph.D. Primary Peritoneal Carcinoma Program . We are working to put together a Family and Friends Advisory Council for the The Beverlee Zell-Tamis, Ph.D. Primary Peritoneal Carcinoma Program . If interested, please email us at BeverleeZell-TamisProgram@askican.org.
If you would like to become involved as a donor and supporter or a member of our Cancer Research Literature team as a Research Team Leader (medical school students, physicians, nurses, and post-docs only please), you may reach us at BeverleeZell-TamisProgram@askican.org.
